列管於運動禁藥監控計畫中的Telmisartan__臺灣人文及社會科學引文索引資料庫

:::

詳目顯示

第 1 筆 / 總合 1 筆

/1頁

來源文獻資料
摘要
外文摘要
引文資料

題名：	列管於運動禁藥監控計畫中的Telmisartan
書刊名：	運動生理暨體能學報
作者：	張值維／陳昭彥／許美智
作者(外文)：	Chang, Chih-wei／Chen, Chao-yen／Hsu, Mei-chich
出版日期：	2016
卷期：	23
頁次：	頁13-22
主題關鍵詞：	血管張力素II接受體阻斷劑；世界運動禁藥管制機構；荷爾蒙及代謝調節劑；高血壓；美度銨；Angiotensin II receptor blocker；World Anti-Doping Agency；Hormone and metabolic modulators；Hypertension；Meldonium
原始連結：	連回原系統網址
相關次數：	被引用次數:期刊(0) 博士論文(0) 專書(0) 專書論文(0) 排除自我引用:0 共同引用:1 點閱:11

背景：Telmisartan是一血管張力素II接受體阻斷劑（angiotensin II receptor blockers），用以治療高血壓及降低心血管風險，它擁有比起其他同類藥物更多的優勢，如一天一錠的用法、老年／腎功能不佳者可服用、更專一的藥效作用等，因而暢銷於世界各地，但也因其擁有能提升運動表現的潛在藥效，使它在體育界備受關注。Telmisartan藉由AMP-activated protein kinase （AMPK）/ peroxisome proliferator activated receptor δ（PPAR δ）路徑預防脂肪合成、增進運動耐力及運動後的氧氣消耗、增加慢肌纖維的比例。在2014年年底，Telmisartan與莎拉波娃所服用的美度銨（Meldonium）同時被世界運動禁藥管制機構（World Anti-Doping Agency, WADA）列入 2015運動禁藥賽內及賽外的監控計畫。現今，美度銨被列入運動禁藥，而Telmisartan則尚在監控計畫中。WADA此時不會對服用Telmisartan之運動員進行懲罰，但正密切監控其是否被濫用，隨時都可能跟美度銨一樣，正式被列入運動禁藥。目的：本文將詳細介紹Telmisartan藥品發展與臨床應用、作用機轉與運動表現的關聯、藥物動力學與檢驗方法及替代藥物的選擇。

以文找文

Background: Telmisartan belongs to angiotensin II receptor blockers and is used for treating essential hypertension and reducing cardiovascular risk. Telmisartan is considered as an attractive and world-wide popular ARB owing to its numerous merits, e.g., the usage of a tablet per day, good tolerance in elderly and patients with renal impairment, and high specificity of action. However, telmisartan is now in a perilous state, because it may potentially elevate exercise performance. Studies have demonstrated that telmisartan may prevent fat synthesis, enhance execise endurance and postexercise oxygen consumption, and increase slow-twitch skeletal muscle fibres via AMP-activated protein kinase (AMPK) / peroxisome proliferator activated receptor δ (PPAR δ) pathway. In the end of 2014, telmisartan and meldonium, which Sharapova took, were simultaneously listed in the 2015 Monitoring Program by the World Anti-Doping Agency (WADA). Nowadays, meldonium is prohibited so far, whereas telmisartan is still in monitoring program. WADA would not make the punishment on athletes who are taking telmisartan, but is currently monitoring the abuse substances seriously. Telmisartan could be officially prohibited in anytime, just like meldonium. Purpose: This literature review introduces the development and clinical indications, mechanism of actions, the link between exercise performance, metabolism and excretion, detection methods as well as alternative medications of telmisartan.

以文找文

期刊論文
1.	張值維、陳昭彥、許美智(20160600)。球后莎拉波娃與運動禁藥美度銨。運動教練科學，42，121-130。延伸查詢
2.	Brunmair, B.、Staniek, K.、Dörig, J.、Szöcs, Z.、Stadlbauer, K.、Marian, V.(2006)。Activation of PPAR-δ in isolated rat skeletal muscle switches fuel preference from glucose tofatty acids。Diabetologia，49，2713-2722。
3.	De Gasparo, M.、Catt, K. J.、Inagami, T.、Wright, J. W.、Unger, T. H.(2000)。International union of pharmacology. XXIII. The angiotens in II receptors。Pharmacological Reviews，52，415-472。
4.	del Rosario Brunetto, M.、Contreras, Y.、Clavijo, S.、Torres, D.、De lgado, Y.、Ovalles, F.(2009)。Determination of losartan, telmisartan, and valsartan by direct injection of human urine into a columnswitching liquid chromatographic system with fluorescence detection。Journal of Pharmaceutical and Biomedical Analysis，50，194-199。
5.	Dinh, D. T.、Frauman, A. G.、Johnston, C. I.、Fabiani, M. E.(2001)。Angiotensin receptors: Distribution, signalling and function。Clinical Science，100，481-492。
6.	Feng, X.、Luo, Z.、Ma, L.、Ma, S.、Yang, D.、Zhao, Z.(2011)。Angiotensin II receptor blocker telmisartan enhances running endurance of skeletal muscle through activation of the PPAR-δ/AMPK pathway。Journal of Cellular and Molecular Medicine，15，1572-1581。
7.	Ferreirós, N.、Dresen, S.、Alonso, R. M.、Weinmann, W.(2007)。Validated quantitation of angiotensin II receptor antagonists (ARA-II) in human plasma by liquidchromatography-tandem mass spectrometry using minimum sample clean-up and investigation of ion suppression。Therapeutic Drug Monitoring，29，824-834。
8.	Fogari, R.、Zoppi, A.、Poletti, L.、Marasi, G.、Mugellini, A.、Corradi, L.(2001)。Sexual activity in hypertensive men treated with valsartan or carvedilol: A crossover study。American Journal of Hypertension，14，27-31。
9.	Gupta, V. K.、Jain, R.、Lukram, O.、Agarwal, S.、Dwivedi, A.(2011)。Simultaneous determination of ramipril, ramiprilat and telmisartan in human plasma using liquid chromatography tandem mass spectrometry。Talanta，83，709-716。
10.	Ferreirós, N.、Iriarte, G.、Alonso, R. M.、Jiménez, R. M.、Ortíz, E.(2008)。Separation and quantitation of several angiotensin II receptor antagonist drugs in human urine by a SPE-HPLC-DAD method。Journal of Separation Science，31，667-676。
11.	He, H.、Yang, D.、Ma, L.、Luo, Z.、Ma, S.、Feng, X.(2010)。Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-δ-dependent pathways。Hypertension，55，869-879。
12.	Li, N. C.、Lee, A.、Whitmer, R. A.、Kivipelto, M.、Lawler, E.、Kazis, L. E.(2010)。Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: Prospective cohort analysis。BMJ，340，b5465。
13.	Li, P.、Wang, Y.、Wang, Y.、Tang, Y.、Fawcett, J. P.、Cui, Y.(2005)。Determination of telmisartan in human plasma by liquid chromatography-tandem mass spectrometry。Journal of Chromatography，828(1/2)，126-129。
14.	Llisterri Caro, J. L.、Lozano Vidal, J. V.、Argaya Roca, M.、Pol Bravo, C.、Aznar Vicente, J.、Ferrario, C. M.(2001)。Sexual dysfunction in hypertensive patients treated with losartan。The American Journal of the Medical Sciences，321(5)，336-341。
15.	Long, Q.、Lei, T.、Feng, B.、Yin, C.、Jin, D.、Wu, Y.(2010)。Peroxisome proliferatoractivated receptor-γ increases adiponectin secretion via transcriptional repression of endoplasmic reticulum chaperone protein ERp44。Endocrinology，151，3195-3203。
16.	McClellan, K. J.、Markham, A.(1998)。Telmisartan。Drugs，56，1039-1046。
17.	Miura, S.、Kiya, Y.、Kanazawa, T.、Imaizumi, S.、Fujino, M.、Matsuo, Y.(2008)。Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state。Molecular Endocrinology，22，139-146。
18.	Narkar, V. A.、Downes, M.、Yu, R. T.、Embler, E.、Wang, Y. X.、Banayo, E.、Evans, R. M.(2008)。AMPK and PPARδ agonists are exercise mimetics。Cell，134(3)，405-415。
19.	Nie, J.、Zhang, M.、Fan, Y.、Wen, Y.、Xiang, B.、Feng, Y. Q.(2005)。Biocompatible in-tube solid-phase microextraction coupled to HPLC for the determination of angiotensin II receptor antagonists in human plasma and urine。Journal of Chromatography，828(1/2)，62-69。
20.	Pavel, J.、Benicky, J.、Murakami, Y.、Sanchez-Lemus, E.、Saavedra, J. M.(2008)。Peripherally administered angiotensin II AT1 receptor antagonists are anti-stress compounds in vivo。Annals of the New York Academy of Sciences，1148，360-366。
21.	Sahebkar, A.、Chew, G. T.、Watts, G. F.(2014)。New peroxisome proliferatoractivated receptor agonists: Potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease。Expert Opinion on Pharmacotherapy，15，493-503。
22.	Sharma, A. M.、Hollander, A.、Koster, J.(2005)。Telmisartan in patients with mild/moderate hypertension and chronic kidney disease。Clinical Nephrology，63，250-257。
23.	Shen, J.、Jiao, Z.、Li, Z. D.、Shi, X. J.、Zhong, M. K.(2005)。HPLC determination of telmisartan in human plasma and its application to a pharmacokinetic study。Die Pharmazie，60，418-420。
24.	Stangier, J.、Schmid, J.、Türck, D.、Switek, H.、Verhagen, A.、Peeters, P. A. M.(2000)。Absorption, metabolism, and excretion of intravenously and orally administered [14C] telmisartan in healthy volunteers。Journal of Clinical Pharmacology，40，1312-1322。
25.	Torrealday, N.、González, L.、Alonso, R. M.、Jiménez, R. M.、Ortiz Lastra, E.(2003)。Experimental design approach for the optimisation of a HPLC-fluorimetric method for the quantitation of the angiotensin II receptor antagonist telmisartan in urine。Journal of Pharmaceutical and Biomedical Analysis，32，847-857。
26.	Vidt, D. G.(2008)。Telmisartan, ramipril, or both in patients at high risk for vascular events。Current Hypertension Reports，10，343-344。
27.	Yan, T.、Li, H.、Deng, L.、Guo, Y.、Yu, W.、Fawcett, J. P.(2008)。Liquid chromatographic-tandem mass spectrometric method for the simultaneous quantitation of telmisartan and hydrochlorothiazide in human plasma。Journal of Pharmaceutical and Biomedical Analysis，48，1225-1229。
28.	Yilmaz, H.、Basan, H.(2015)。Development of a molecularly imprinted solid-phase extraction sorbent for the selective extraction of telmisartan from human urine。Journal of Separation Science，38，1433-1439。
29.	Zaman, M. A.、Oparil, S.、Calhoun, D. A.(2002)。Drugs targeting the reninangiotensin- aldosterone system。Nature Reviews Drug Discovery，1，621-636。
30.	Zankl, A. R.、Ivandic, B.、Andrassy, M.、Volz, H. C.、Krumsdorf, U.、Blessing, E.(2010)。Telmisartan improves absolute walking distance and endothelial function in patients with peripheral artery disease。Clinical Research in Cardiology，99(12)，787-794。
31.	Zhang, H.、Jiang, Y.、Wen, J.、Zhou, T.、Fan, G.、Wu, Y.(2009)。Rapid determination of telmisartan in human plasma by HPLC using a monolithic column with fluorescence detection and its application to a bioequivalence study。Journal of Chromatography，877，3729-3733。
32.	Zhang, M.、Wei, F.、Zhang, Y. F.、Nie, J.、Feng, Y. Q.(2006)。Novel polymer monolith microextraction using a poly (methacrylic a cid- e thyl ene glycol dimethac rylat e) monolith and its application to simultaneous analysis of several angiotensin II receptor antagonists in human urine by capillary zone electrop。Journal of Chromatography，1102，294-301。

圖書
1.	唐正乾(2012)。當代藥理學。台北市：合記圖書。延伸查詢

其他
1.	Behar, M.(2011)。Faster. Higher. Squeakier. Outside，https://www.outsideonline.com/1898181/faster-higher-squeakier。
2.	Boehringer Ingelheim GmbH(2013)。Micardis® Tablets 40 mg/80 mg，http://www.fda.gov.tw/MLMS/ShowFile.aspx?LicId=02023162&Seq=003&Type=9。
3.	World Anti-Doping Agency(2008)。The 2009 prohibited list: International standard，https://wada-main-prod.s3.amazonaws.com/resources/files/WADA_Prohibited_List_2009_EN.pdf。
4.	World Anti-Doping Agency(2011)。The 2012 prohibited list: International standard，https://wada-main-prod.s3.amazonaws.com/resources/files/WADA_Prohibited_List_2012_EN.pdf。
5.	World Anti-Doping Agency(2014)。The 2014 Monitoring Program，https://wada-main-prod.s3.amazonaws.com/resources/files/WADAMonitoring-Program-2014-EN.pdf。
6.	World Anti-Doping Agency(2015)。The 2016 prohibited list: International standard，https://wada-main-prod.s3.amazonaws.com/resources/files/wada-2016-prohibited-list-en.pdf。

圖書論文
1.	Schwinghammer, T. L.(2015)。Section 2: Cardiovascular disorders。Pharmacotherapy handbook。New York, NY：McGraw-Hill Education/Medical。

推文
推薦
引用網址
引用嵌入語法
轉寄

top

:::

相關期刊
相關論文
相關專書
相關著作
熱門點閱

1.	大專運動員對「運動禁藥查詢系統App」的使用動機與滿意度
2.	球后莎拉波娃與運動禁藥美度銨

無相關博士論文

無相關書籍

無相關著作

無相關點閱

QR Code

臺灣人文及社會科學引文索引資料庫系統

詳目顯示

臺灣人文及社會科學引文索引資料庫